Dr. Vicky Makker, MD
Hematology & Oncology (Hematology & Oncology Physician)
- Medicare participating
At a glance
- Medical school
- University of Florida College of Medicine (2003)
- Years since graduation
- 23
- In the NPI registry since
- 2008
- Medicare patients seen, 2024
- 137
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 2003Medical school: University of Florida College of Medicine
- 2008Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Hematology & Oncology Physician primary
NY license 239045-1
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Medical groups
- Memorial Developmental Chemo Group (48 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 137
- Services billed
- 525
- Patients’ average age
- 74
| Service | Times | Patients |
|---|---|---|
| Established patient office or other outpatient visit, 30-39 minutes | 483 | 122 |
| Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | 40 | 19 |
| New patient office or other outpatient visit, 60-74 minutes | 17 | 17 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Industry-funded research
Named as a principal investigator on 9 industry-funded studies in 2025, from 4 companies. The companies reported $2,278,129 in research payments for these studies, mostly to the institutions running them.
- A Phase II Trial of Pembrolizumab plus Lenvatinib for the Treatment of Patients with Advanced Uterine Carcinosarcoma
Merck Sharp & Dohme LLC - Phase 2 Multicenter Open-label Study to Evaluate the Efficacy and Safety of Trastuzumab Deruxtecan (T-DXd DS-8201a) for the Treatment of Selected HER2 Expressing Tumours (DESTINY-PanTumor02)
AstraZeneca Pharmaceuticals LP - A Phase II, Multicentre, Open-label, Master Protocol to Evaluate the Efficacy and Safety of Datopotamab-Deruxtecan Dato-DXd as Monotherapy and in Combination with Anticancer Agents in Patients with Advanced Metastatic…
AstraZeneca Pharmaceuticals LP - STUDY NAME#A Phase II Trial of Pembrolizumab plus Lenvatinib for the Treatment of Patients with Advanced Uterine and Ovarian Carcinosarcomas
Merck Sharp & Dohme LLC - A Phase 3 Randomized, Open-Label, Study of Pembrolizumab MK-3475 Plus Lenvatinib E7080,MK-7902 Versus Chemotherapy for First-line Treatment of Advanced or Recurrent Endometrial Carcinoma LEAP-001
Merck Sharp & Dohme LLC - A Phase 3 Randomized, Open-label, Active-comparator Controlled Clinical Study of Pembrolizumab vs. Platinum Doublet Chemotherapy in Participants With Mismatch Repair Deficient dMMR Advanced or Recurrent Endometrial Ca…
Merck Sharp & Dohme LLC - A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination with Pembrolizumab Versus Treatment of Physician s Choice in Subjects with Advanced Endometrial Cancer
Merck Sharp & Dohme LLC - A Randomized, Double-Blind, Phase 3 Trial of Maintenance with Selinexor/Placebo After Combination Chemotherapy for Patients with Advanced or Recurrent Endometrial Cancer
Karyopharm Therapeutics Inc. - Study name not reported
Organon Llc
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.